The Research Luxembourg COVID-19 (coronavirus) task force has announced the launch of "CON-VINCE", a study that aims to evaluate the dynamics of the spread of coronavirus within the Luxembourgish population.
The project is one of the several initiatives put in place under the aegis of the task force to help contain the current pandemic. It will test about 1,500 people for the presence of the SARS-CoV-2 virus and follow up only the asymptomatic and mildly symptomatic individuals. The aim is to generate accurate data on the transmission of the disease, ultimately assisting policy-makers in taking evidence-based decisions over the course of the coming weeks.
Asymptomatic individuals, often referred to as "silent carriers", and mildly symptomatic carriers are known to play a significant role in the spread of the virus. However, they currently remain largely unassessed, since diagnostic testing is performed predominantly on people with clear COVID-19 symptoms. In order to put in place effective measures to stave off the COVID-19 infection, it is considered crucial to systematically test a representative sample of the population in order to identify all individuals carrying the SARS-CoV-2 virus, regardless of their symptoms.
In this context, CON-VINCE launched yesterday with the aim of testing approximately 1,500 participants over the age of 18 and detecting the three main groups of asymptomatic or mildly symptomatic people. Specifically, these include individuals who are "virus-free" and therefore asymptomatic, people who are currently infected but present mild or no symptoms, and those who were infected but are currently free of the virus.
Panel participants will be recruited by TNS ILRES and tested for SARS-CoV-2 through a specific molecular biology technique. The analyses will initially be carried out on collected nasal and pharyngeal swabs and subsequently extended to blood and other sample types. Participants testing positive for SARS-CoV-2 but displaying mild or no symptoms will be followed up over one year, together with virus-free individuals. Conversely, symptomatic patients will be excluded from the study and undergo regular treatment instead.
Prof. Rejko Krüger, Director of Transversal Translational Medicine at the Luxembourg Institute of Health (LIH) and coordinator of the "CON-VINCE" study, commented: "To the best of our knowledge, asymptomatic carriers are not systematically monitored in any of the countries affected by the COVID-19 pandemic. Therefore, at present, no comprehensive data on the epidemiology and dynamics of the disease exist. CON-VINCE aims to fill this gap by providing reliable information on the nature, prevalence and transmission modality of COVID-19 in the Grand Duchy, therefore guiding national and international decision-makers in mounting an effective public health, political and economic response to the pandemic".
Prof. Ulf Nehrbass, Chief Executive Officer at LIH and spokesperson of the Research Luxembourg COVID-19 task force, added: "In parallel, the project will also allow us to track the psychological and socio-economic impact of long-term containment measures on the general population and help us define clearer timeframes for lifting the current stringent confinement strategies".
Paulette Lenert, Luxembourg's Minister of Health, also commented: "The CON-VINCE study represents the logical next step of the extensive testing of our population to better prevent the spread of the virus. We continue to put huge efforts to gather the best information in order to get ahead of the virus".
The CON-VINCE study is led by a consortium of Luxembourgish research institutions, including LIH and the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg. The Luxembourg National Research Fund (FNR) is co-funding the study with an amount of €1.4 million. The market research company TNS-ILRES, Ketterthill, Laboratoires Réunis and BioneXt Lab are associated partners in this study.